Merck KGaA Enters Partnership With China`s Hengrui for Up to $1.5 Bln
As Elevar Therapeutics and Hengrui Pharmaceuticals await an FDA decision on their combination therapy for newly diagnosed unresectable liver cancer—approved in China back in February—the partners are lining up a new global commercialization pact.
Strides's Generic Gadobutrol Receives Approval in the U.S.